Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024 Guidelines
| Authors: | Bryce, A. H.; Agarwal, N.; Beltran, H.; Hussain, M. H.; Sartor, O.; Shore, N.; Antonarakis, E. S.; Armstrong, A. J.; Calais, J.; Carducci, M. A.; Dorff, T. B.; Efstathiou, J. A.; Gleave, M.; Gomella, L. G.; Higano, C.; Hope, T. A.; Iagaru, A.; Morgans, A. K.; Morris, D. S.; Morris, M. J.; Petrylak, D. P.; Reiter, R. E.; Rettig, M. B.; Ryan, C. J.; Sellinger, S. B.; Spratt, D. E.; Srinivas, S.; Tagawa, S. T.; Taplin, M. E.; Yu, E. Y.; Zhang, T.; McKay, R. R.; Koo, P. J.; Crawford, E. D. |
| Title: | Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024 |
| Abstract: | Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions that are unanswered by prospective trials but nonetheless encountered in day-to-day practice. To address these practical questions, the 2024 US Prostate Cancer Conference (USPCC 2024) was created to generate US-focused expert clinical decision-making guidance for circumstances in which level 1 evidence is lacking. At the second annual USPCC meeting (USPCC 2024), a multidisciplinary panel of experts convened to discuss ongoing clinical challenges related to 5 topic areas: biochemical recurrence; metastatic, castration-sensitive prostate cancer; poly [ADP-ribose] polymerase inhibitors; prostate-specific membrane antigen radioligand therapy; and metastatic, castration-resistant prostate cancer. Through a modified Delphi process, 34 consensus recommendations were developed and are intended to provide clinicians who manage prostate cancer with guidance related to the implementation of novel treatments and technologies. In this report, the authors review the areas of consensus identified by the USPCC 2024 experts and evaluate ongoing unmet needs regarding translational application of the current clinical evidence. © 2024 The Author(s). Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. |
| Keywords: | gene mutation; overall survival; cancer recurrence; systemic therapy; united states; lymph node metastasis; clinical practice; evidence based medicine; evidence-based medicine; prostate specific antigen; consensus; quality of life; apoptosis; neoplasm recurrence, local; evidence based practice; practice guideline; pathology; risk factor; histology; prostate cancer; prostate-specific antigen; prostatic neoplasms; tumor suppressor gene; blood; dosimetry; prostatectomy; heterozygosity; cardiovascular risk; tumor recurrence; mismatch repair; prostate tumor; prostate biopsy; practice guidelines as topic; tamoxifen; radical prostatectomy; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor; androgen receptor; decision making; genetic screening; androgen deprivation therapy; gynecomastia; biochemical recurrence; therapy; predictive value; creatinine clearance; personalized medicine; castration resistant prostate cancer; abiraterone; radioligand; poly(adenosine diphosphate ribose); lutetium 177; estimated glomerular filtration rate; enzalutamide; advanced prostate cancer; humans; human; male; article; circulating tumor dna; prostatic neoplasms, castration-resistant; liquid biopsy; poly(adp-ribose) polymerase inhibitors; positron emission tomography-computed tomography; radioligand therapy; consensus recommendations; androgen receptor pathway inhibitors; poly(adp-ribose) polymerase (parp) inhibitors |
| Journal Title: | Cancer |
| Volume: | 131 |
| Issue: | 1 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2025-01-01 |
| Start Page: | e35612 |
| Language: | English |
| DOI: | 10.1002/cncr.35612 |
| PUBMED: | 39616467 |
| PROVIDER: | scopus |
| PMCID: | PMC11694557 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
